Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chau Dang

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
The end of an era: shall we move forward?Chau Dang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2006
Can granulocyte-colony stimulating factor worsen anemia?Chau Dang, Clifford Hudis
The Breast Journal|December 23, 2014
The development of dose-dense adjuvant chemotherapyClifford Hudis, Chau Dang
Journal of the National Cancer Institute|May 29, 2008
The taxane limbo: how low can we go?Clifford Hudis, Chau Dang
Clinical Breast Cancer|June 13, 2006
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the icebergChau Dang, Clifford Hudis
Journal of the National Cancer Institute|April 29, 2020
Trastuzumab: Weighing the Benefits and the RisksAnne H Blaes, Chau Dang
Cancer Treatment Reviews|September 16, 2003
Dose-dense treatment prolongs disease-free survival of women with node positive breast cancerChau Dang, Andrew D Seidman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Dose-dense chemotherapy with trastuzumab is an appropriate optionChau Dang, Larry Norton, Clifford Hudis
Clinical Breast Cancer|September 1, 2010
Adjuvant taxanes: more to the storyDevika Gajria, Andrew Seidman, Chau Dang
Breast (Edinburgh, Scotland)|January 21, 2012
Epirubicin: is it like doxorubicin in breast cancer? A clinical reviewMustafa Khasraw, Richard Bell, Chau Dang
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
The end of an era: shall we move forward?Chau Dang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2006
Can granulocyte-colony stimulating factor worsen anemia?Chau Dang, Clifford Hudis
The Breast Journal|December 23, 2014
The development of dose-dense adjuvant chemotherapyClifford Hudis, Chau Dang
Journal of the National Cancer Institute|May 29, 2008
The taxane limbo: how low can we go?Clifford Hudis, Chau Dang
Clinical Breast Cancer|June 13, 2006
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the icebergChau Dang, Clifford Hudis
Journal of the National Cancer Institute|April 29, 2020
Trastuzumab: Weighing the Benefits and the RisksAnne H Blaes, Chau Dang
Cancer Treatment Reviews|September 16, 2003
Dose-dense treatment prolongs disease-free survival of women with node positive breast cancerChau Dang, Andrew D Seidman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2008
Dose-dense chemotherapy with trastuzumab is an appropriate optionChau Dang, Larry Norton, Clifford Hudis
Clinical Breast Cancer|September 1, 2010
Adjuvant taxanes: more to the storyDevika Gajria, Andrew Seidman, Chau Dang
Breast (Edinburgh, Scotland)|January 21, 2012
Epirubicin: is it like doxorubicin in breast cancer? A clinical reviewMustafa Khasraw, Richard Bell, Chau Dang
Pageof 8